Due to the international acceleration of COVID-19 vaccination, the use of a post-vaccination sample cohort would now be available and could provide significant insight into the future of SARS-CoV-2 antibody testing. had the highest clinical overall performance detecting antibodies to S trimer and RBD in 100% (n= 25) of known positive samples. Both the Magnetic Luminex Assay and LABScreen COVID Plus Assay showed significant diagnostic accuracy with sensitivities of 90% and 88% respectively. The Luminex xMAP SARS-CoV-2 Multi-Antigen IgG Assay shown limited detection of antibodies to the S antigen resulting in a level of sensitivity of 68%. == Summary == Luminex-based assays provide a appropriate serological method for multiplex detection of SARS-CoV-2 specific antibodies, with each assay able to detect antibodies to a minimum of 3 different SARS-CoV-2 antigens. Assay assessment identified there is moderate overall performance variability between manufacturers and further inter-assay variance of antibodies recognized to different SARS-CoV-2 antigens. Keywords:COVID-19, SARS-CoV-2, Antibody screening, Luminex, IDO-IN-12 Serology IDO-IN-12 == 1. Intro == Since the 1st instances of a pneumonia of unfamiliar cause were reported in Wuhan, China in December 2019, the causative agent recognized to be severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) offers spread across the globe (Campbell et al., 2021). The acknowledgement of this fresh highly transmissible computer virus and its quick spread across the world led the World Health Business (WHO) to declare this as a global pandemic on 11th March 2020 (Shaw et al., 2020). Illness with SARS-CoV-2 can cause the disease known as COVID-19 and offers varying medical manifestations in individuals, ranging from slight symptoms to severe and rapidly progressing disease (Wu et al., 2020). From the beginning of the pandemic, the disease in its most severe form quickly proved to be fatal inside a minority of instances. Despite a relatively low fatality rate, due to the exponential case figures the disease offers accounted for >6.9 million deaths worldwide as of May 31st, 2022 (Sachs et al., 2022). Currently, molecular screening through real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) of nasopharyngeal swabs is used for medical diagnostic screening of COVID-19 illness (Wang et al., 2020). Whilst this is adequate for analysis in the majority of instances, it does not provide an insight into how an individual’s body is responding to illness. Serological analysis is definitely a fundamental tool for the detection of antibodies generated in response to illness (Rai et al., 2021). It provides an effective screening method for recognition of previous illness and has a wide range of medical applications (Winter season and Hegde, 2020). Epidemiologically, the use of serological assays for SARS-CoV-2 antibody detection enables accurate estimations of illness prevalence and incidence, which are vital for outbreak control strategy planning (Whitman et al., 2020). Clinically, serological assays have an important part in COVID-19 analysis in individuals whose symptoms are highly suggestive of illness but who are screening bad by molecular methods (Xiang et al., 2020). A further critical use of serological assays is definitely evaluating immune response post vaccination (Tang et al., 2020), with an ideal vaccine stimulating the immune system to generate neutralizing antibodies to stop viral access into sponsor cells (Hofman et al., 2021). The ability to evaluate immune response to vaccination is definitely of improved importance for individuals who are immunocompromised, as studies on well-established vaccines display substantial variance in production of neutralizing antibodies and duration of vaccine induced immunity (Windpessl et al., 2021). Despite the obvious need for accurate and reliable serological assays in the COVID-19 pandemic response, there was clearly at first a lack of information concerning their meant applications and their medical utility remained mainly uncharacterized (Kopel et al., 2021;Bohn et al., 2020). In April 2021, the WHO published international requirements for SARS-CoV-2 antibody screening in order to attempt harmonization of serological screening (Baldanti et al., IDO-IN-12 2022). Although IDO-IN-12 several studies Col1a1 have been carried out to compare the medical overall performance of antibody detection assays, you will find limited comparisons of assays overall performance characteristics against specified SARS-CoV-2 antigens. A comprehensive review carried out by a Danish study compared 16 different serological assays and reported the level of sensitivity and specificity of the assays (Harritshj et al., 2021). However, this study did not directly compare the overall performance features of each assay for a given antigen. This.